<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098137</url>
  </required_header>
  <id_info>
    <org_study_id>AFNET-B10</org_study_id>
    <secondary_id>Grant No 01GI0204</secondary_id>
    <nct_id>NCT00098137</nct_id>
  </id_info>
  <brief_title>Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial (ANTIPAF Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrial Fibrillation Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      Blocking the angiotensin (AT) II type 1 receptor (Olmesartan) reduces the incidence of&#xD;
      episodes of atrial fibrillation in patients with paroxysmal atrial fibrillation during 12&#xD;
      months by more than 25% compared to standard medication without angiotensin II type 1&#xD;
      receptor.&#xD;
&#xD;
      A total of 422 subjects will be included in the two study groups. The treatment arm will&#xD;
      receive 40mg Olmesartan per day, the remaining patients will receive placebo. Follow-up is 12&#xD;
      months. Daily Tele-ECG recordings will determine the cardiac rhythm and asymptomatic episodes&#xD;
      of atrial fibrillation (AF) every day. Concomitant therapy with AV-nodal blocking drugs are&#xD;
      allowed during the study. In case of severe AF-induced symptoms, an antiarrhythmic &quot;recovery&#xD;
      medication&quot; (amiodarone) is allowed during follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, central randomization, two treatment groups, stratified by beta-blocker use.&#xD;
      211 patients in each treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)</measure>
    <time_frame>12 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of a documented relapse of atrial fibrillation</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of a symptomatic documented episode of AF</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to persistent atrial fibrillation</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to prescription of the recovery-medication</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for cardiovascular reasons (-&gt; Endpoint review)</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intermediate medical visits for cardiovascular reasons (-&gt; Endpoint review) without hospitalization</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cerebrovascular events</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>Heart Disease</condition>
  <condition>Arrhythmia</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Olmesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan tablet, 1 in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, 1 in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <arm_group_label>Olmesartan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented paroxysmal atrial fibrillation: ECG documentation of atrial fibrillation at&#xD;
             least in one ECG recorded during the last 2 months prior to randomization plus&#xD;
             additional ECG recording of sinus rhythm at least 12 hours after the above mentioned&#xD;
             ECG documentation.&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Patient informed orally and in writing&#xD;
&#xD;
          -  Written informed consent of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Strong clinical evidence for therapy with AT II/ACE inhibitors&#xD;
&#xD;
          -  AT II/ACE inhibitor therapy within the last month&#xD;
&#xD;
          -  Therapy with antiarrhythmic agents of class I or class III within the last month,&#xD;
             therapy with amiodarone within the last 3 months&#xD;
&#xD;
          -  Direct current (DC) cardioversion within the last 3 months&#xD;
&#xD;
          -  Symptomatic bradycardia&#xD;
&#xD;
          -  Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardiac&#xD;
             algorithm in use&#xD;
&#xD;
          -  Cardiac surgery or cardiac catheter ablation within the last 3 months&#xD;
&#xD;
          -  Typical angina pectoris symptoms at rest or during exercise&#xD;
&#xD;
          -  Known coronary artery disease with indication for intervention&#xD;
&#xD;
          -  Valvular disease &gt; II degree&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
          -  Diastolic blood pressure &gt; 110mm Hg at rest&#xD;
&#xD;
          -  Symptomatic arterial hypotension&#xD;
&#xD;
          -  Known renal artery stenosis&#xD;
&#xD;
          -  Serum creatinine &gt; 1.8 mval/l&#xD;
&#xD;
          -  Relevant hepatic or pulmonary disorders&#xD;
&#xD;
          -  Hyperthyroidism manifested clinically and in laboratory&#xD;
&#xD;
          -  Known drug intolerance for AT II inhibitors&#xD;
&#xD;
          -  Females who are pregnant or breast feeding&#xD;
&#xD;
          -  Females of childbearing potential who are not using a scientifically accepted method&#xD;
             of contraception&#xD;
&#xD;
          -  Participation in a clinical trial within the last 30 days&#xD;
&#xD;
          -  Drug addiction or chronic alcohol abuse&#xD;
&#xD;
          -  Legal incapacity, or other circumstances which would prevent the patient from&#xD;
             understanding the aim, nature or extent of the clinical study&#xD;
&#xD;
          -  Evidence of an uncooperative attitude&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Meinertz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Goette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Magdeburg</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.kompetenznetz-vorhofflimmern.de</url>
    <description>Homepage of the German AF Network</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 3, 2004</study_first_submitted>
  <study_first_submitted_qc>December 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2004</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>angiotensin II</keyword>
  <keyword>angiotensin receptor antagonist</keyword>
  <keyword>drug</keyword>
  <keyword>controlled clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 19, 2013</submitted>
    <returned>October 22, 2013</returned>
    <submitted>October 25, 2013</submitted>
    <returned>December 13, 2013</returned>
    <submitted>February 20, 2014</submitted>
    <returned>April 1, 2014</returned>
    <submitted>September 8, 2020</submitted>
    <returned>September 28, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

